TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36296952
Drug: Fruits and
Normalized name: Aminobenzoic Acid/Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Choline Bitartrate/Copper/Cyanocobalamin/Folic Acid/Inositol/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phosphorus/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin E/Zinc 5 MG-180 MG-300 MCG-120 MG-30 MCG-5 MG-2 MG-18 MCG-800 MCG-5 MG-150 MCG-18 MG-100 MG-2 MG-20 MG-30 MG-15 MG-2 MG-5.1 MG-4.5 MG-2250 MCG-7 MG-5 MG Oral Tablet [MEGAVITE WITH FRUITS AND VEGGIES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruits and vegetables containing phenylalanine 76−100 mg/100 g, additional intake of 50 mg/day and then 100 mg/day
Study: 36296952
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein sources, additional intake of 50 mg/day and then 100 mg/day
Study: 32032651
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (after correction for confounders)
Study: 36108767
Drug: N-acetylcysteine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine combined with insulin
Study: 34245368
Drug: Chlorpheniramine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (0.1 mg/kg in 100 ml normal saline)
Study: 34245368
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml normal saline)
Study: 34157772
Drug: Mozart's double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mozart's double piano sonata exposure for 14 days, twice per day
Study: 33046607
Drug: Multistrain probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistrain probiotics capsules (n = 34)
Study: 33259163
Drug: Acid suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid suppression alone (4 weeks' proton pump inhibitor [PPI])
Study: 33259163
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (PPI + feeding modifications and PPI alone)
Study: 33259163
Drug: Infants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants with continued PPI therapy
Study: 35351537
Drug: Distance-guided deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distance-guided deep learning method for dose prediction
Study: 33091520
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cell (BM MNC) therapy
Study: 36029019
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for cardiovascular disease using low-dose computed tomography, limb blood pressure measurement, telemetric assessment of heart rhythm, cholesterol and HgbA1c measurements.
Study: 33322192
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation of brimonidine and timolol BID
Study: 33322192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical hypotensive treatment)
Study: 33209881
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg/day)
Study: 33840725
Drug: Treatment compliance
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment compliance
Study: 32325006
Drug: Instagram posts
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instagram posts regarding antidepressant use
Study: 34732660
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (COM) - MET 500 mg TID, exenatide 2 mg QW
Study: 35362766
Drug: Salmon fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon fish protein supplement
Study: 35691568
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg empagliflozin
Study: 35395957
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 14 days
Study: 34536993
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral superficial cervical plexus block (BSCPB) with 7.5 ml of ropivacaine 0.5% on each side
Study: 32933552
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COVID-19
Study: 35202848
Drug: Metformin (25mg/cat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (25mg/cat PO/q24h for 30 days)
Study: 35202848
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (20 mg intramuscularly)
Study: 35295331
Drug: Carbocysteine oral
Normalized name: carbocysteine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocysteine oral solution (mint taste)
Study: 35295331
Drug: Carbocysteine oral
Normalized name: carbocysteine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocysteine oral solution (strawberry taste)
Study: 33277607
Drug: 810 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 810 nm diode laser application as an adjunct to non-surgical periodontal therapy (NPT)
Study: 33277607
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NPT) without diode laser
Study: 38046082
Drug: Early goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal-directed therapy
Study: 36345020
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (ESWT)
Study: 36345020
Drug: Sham extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham extracorporeal shock wave therapy (sham‐ESWT)
Study: 35357564
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication
Study: 32192595
Drug: Dienogest (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest (1 mg/day, orally)
Study: 34018147
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin regimen (40 mg/day atorvastatin)
Study: 34515341
Drug: Reflexology (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology (higher dose after nonresponse)
Study: 34515341
Drug: Meditative practices
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditative practices (higher dose after nonresponse)
Study: 32220916
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA)
Study: 39262902
Drug: MDMA-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted therapy (MDMA-AT)
Study: 33642523
Drug: SO‐1105 (Miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: SO‐1105 (Miconazole Mucoadhesive Tablets)
Study: 32677897
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Control group, n=118)
Study: 33731291
Drug: Traditional dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional dorsal digital nerve block (two-injection)
Study: 33731291
Drug: Subcutaneous volar
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous volar nerve block
Study: 36349596
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (2 mg) and intranasal oxytocin (24 IU)
Study: 36349596
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo and intranasal oxytocin
Study: 36349596
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol and intranasal placebo
Study: 36349596
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo and intranasal placebo
Study: 34901264
Drug: IV hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV hydrocortisone administration prior to hemodialysis for 3 consecutive sessions
Study: 34901264
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml saline) administered during 3 intervention-free sessions
Study: 32108732
Drug: Topical estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estriol (E) - vaginal cream, daily application, 0.5 mg/d
Study: 35062340
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone in addition to oral prednisolone therapy
Study: 35513842
Drug: $333 monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: $333 monthly cash gift
Study: 35513842
Drug: $20 monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: $20 monthly cash gift (Control)
Study: 32706159
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g okra powder blended in 150 g conventional yogurt
Study: 32269237
Drug: HOPE-L (Hypothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOPE-L (Hypothermic Oxygenated Perfusion for Liver)
Study: 32269237
Drug: SCS-L (Static
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCS-L (Static Cold Storage for Liver)
Study: 32269237
Drug: SCS-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCS-L
Study: 32269237
Drug: HOPE-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOPE-L
Study: 36068945
Drug: Keverprazan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keverprazan 30 mg
Study: 34816682
Drug: Dienogest (Vissane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest (Vissane 2 mg tablet)
Study: 33781234
Drug: Calcium 5
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 5 group (5 mg/kg calcium gluconate)
Study: 33781234
Drug: Calcium 10
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 10 group (10 mg/kg calcium gluconate)
Study: 33402159
Drug: Metformin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (with lifestyle intervention)
Study: 35617960
Drug: Informational video
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational video used to supplement standard in-person verbal and written consent
Study: 35718205
Drug: VLA2001 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLA2001 high dose
Study: 34730529
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of IV and local tranexamic acid
Study: 33838657
Drug: Methylprednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2 mg/kg/day)
Study: 33838657
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/day)
Study: 37145232
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terlipressin (2 mg/day) and noradrenaline (starting at 0.5 mg/h, increased to 3 mg/h)
Study: 33719268
Drug: Sham operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham operation group (normal saline injection after tracheal exposure, n=10)
Study: 35737855
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day ETV
Study: 35737855
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day ETV maleate
Study: 35986241
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (counselling with pictogram-enhanced medication instructions and smartphone medication reminders)
Study: 32737072
Drug: Ozanimod HCl
Normalized name: ozanimod HCl
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ozanimod HCl 0.5 mg/d
Study: 32737072
Drug: Ozanimod HCl
Normalized name: ozanimod HCl
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ozanimod HCl 1 mg/d
Study: 34526429
Drug: Ranitidine Bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine Bismuth Citrate (RBC) pretreatment for 2 weeks before standard triple therapy
Study: 34526429
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (esomeprazole, amoxicillin, and clarithromycin for 7 days)
Study: 33022718
Drug: Control (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conventional treatments by atropine and pralidoxime)
Study: 36201971
Drug: Lung recruitment
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung recruitment associated with positive end-expiratory pressure titration according to the best respiratory system compliance
Study: 33210238
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity (greater average daily energy expenditure)
Study: 35283083
Drug: Ibuprofen (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (median usage of 2 tablets of 800 mg)
Study: 35283083
Drug: Oxycodone/acetaminophen (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen (median usage of one-half of a 5/325mg tablet)
Study: 35522872
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for OA and diabetes mellitus according to international recommendations
Study: 35522872
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for OA and diabetes mellitus according to international recommendations + drug alpha-lipoic acid
Study: 32381018
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m2 on days 1 and 8) with Tmab (8 mg/kg then 6 mg/kg) and Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle
Study: 32381018
Drug: Taxane (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane (docetaxel 75 mg/m2 on day 1 or paclitaxel 80 mg/m2 on days 1, 8, and 15) with Tmab (8 mg/kg then 6 mg/kg) and Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle
Study: 34180407
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with pulsed ultrasound and IF current (CTPI)
Study: 36421046
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg
Study: 35322672
Drug: GALACTIC-HF–ineligible cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: GALACTIC-HF–ineligible cohort not taking guideline-directed medical therapy (GDMT)
Study: 33819614
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) treatment
Study: 35705334
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) with risk factor modification (RFM)
Study: 34895712
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) (10 mL)
Study: 36069803
Drug: Ibuprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2 × 600‐mg doses)
Study: 34894070
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (1 mg/kg/d)
Study: 32811531
Drug: hUC-MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hUC-MSC treatment group
Study: 33793299
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg once daily for 13 cycles in addition to endocrine therapy (ET)
Study: 33793299
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 13 cycles in addition to endocrine therapy (ET)
Study: 33125702
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid
Study: 32520418
Drug: Active Beet+GFJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Beet+GFJ (250 mL grapefruit juice + 70 mL beetroot juice)
Study: 32520418
Drug: Active Beet+H2O
Normalized name: BEET
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Beet+H2O (250 mL water + 70 mL beetroot juice)
Study: 34593015
Drug: Therapist-supported internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-supported internet-delivered behaviour therapy (BIP TIC) for 10-12 weeks
Study: 35774045
Drug: CLS02021 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLS02021 cream
Study: 33711654
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 μg d3‐vitamin)
Study: 35579642
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (initially 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning by 8 mg/d/mo)
Study: 35579642
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (reduced dose 0.4 mg/kg/d, maximum 32 mg/d, weaning by 4 mg/d/mo)
Study: 34300310
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 µg/kg/h)
Study: 33630408
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (300 mg potassium nitrate/day)
Study: 33630408
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg potassium chloride/day)
Study: 33129278
Drug: Free medications
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free medications
Study: 35025817
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly subcutaneous injection
Study: 33360163
Drug: MS-222 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-222 at 300 mg/L
Study: 33360163
Drug: MS-222 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-222 at 100 mg/L
Study: 33237254
Drug: #Tamojunto school‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: #Tamojunto school‐based drug prevention program
Study: 33930187
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter with 500 ml weight attached
Study: 35169169
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (placebo)
Study: 32048365
Drug: Saffron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron supplement (100 mg/day)
Study: 36125279
Drug: Lasmiditan 200
Normalized name: lasmiditan 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 200 mg
Study: 32093628
Drug: Lasmiditan 100
Normalized name: lasmiditan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 100 mg and 200 mg
Study: 34059274
Drug: 1.5% dipotassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% dipotassium oxalate monohydrate (KOX) oral rinse
Study: 39236780
Drug: Lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusion
Study: 35064823
Drug: Prophylactic long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic long-acting G-CSF
Study: 35064823
Drug: Prophylactic standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic standard G-CSF
Study: 35732385
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (0.05 mg/kg)
Study: 35732385
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 0.01 mL/kg)
Study: 33121474
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (10 ml propofol with 1 ml 2% lidocaine), 0.5‐1 mg/kg before endotracheal suctioning
Study: 32627619
Drug: Transoral CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral CO2 laser therapy
Study: 33218508
Drug: Pilates Matwork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates Matwork exercises (50 min, twice a week for 4 months)
Study: 33977744
Drug: Above-knee lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Above-knee lateral approach (Group L)
Study: 34535300
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 1000 IU of 4F-PCC
Study: 34535300
Drug: Variable dosing
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dosing of 4F-PCC
Study: 36092193
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii (Strains O/C, N/R, SIN and T) suspension available as Enterogermina® at the dose of 2 billion spores/5 ml twice daily for 8 weeks along with conventional treatment.
Study: 36092193
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only.
Study: 36092193
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii supplementation along with conventional treatment.
Study: 34233966
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and egg oral immunotherapy (OIT) administered once daily for 18 months
Study: 34233966
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily for 18 months
Study: 33275278
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D
Study: 33113161
Drug: Hyoscine‐N‐butylbromide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butylbromide 20 mg (1 mL)